Nothing Special   »   [go: up one dir, main page]

Uversky et al., 2002 - Google Patents

Synergistic effects of pesticides and metals on the fibrillation of α-synuclein: implications for Parkinson's disease

Uversky et al., 2002

Document ID
11154905196061676122
Author
Uversky V
Li J
Bower K
Fink A
Publication year
Publication venue
Neurotoxicology

External Links

Snippet

Aggregation of α-synuclein has been implicated in the formation of proteinaceous inclusions in the brain (Lewy bodies, Lewy neurites) that are characteristic of neurodegenerative diseases, such as Parkinson's disease (PD) and dementia with Lewy bodies (DLBs). The …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals

Similar Documents

Publication Publication Date Title
Uversky et al. Synergistic effects of pesticides and metals on the fibrillation of α-synuclein: implications for Parkinson’s disease
Santner et al. Metalloproteomics and metal toxicology of α-synuclein
Huat et al. Metal toxicity links to Alzheimer's disease and neuroinflammation
Wang et al. Iron pathophysiology in Alzheimer’s diseases
Gaeta et al. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Zatta et al. Alzheimer's disease, metal ions and metal homeostatic therapy
Mor et al. Dynamic structural flexibility of α-synuclein
Rekas et al. Interaction of the molecular chaperone αB-crystallin with α-synuclein: effects on amyloid fibril formation and chaperone activity
Muller et al. Iron dysregulation in Huntington's disease
Mattson et al. Neuronal and glial calcium signaling in Alzheimer’s disease
Ruf et al. Different effects of α-synuclein mutants on lipid binding and aggregation detected by single molecule fluorescence spectroscopy and ThT fluorescence-based measurements
Fourie et al. Dietary zinc supplementation prevents autism related behaviors and striatal synaptic dysfunction in Shank3 exon 13–16 mutant mice
Yang et al. Mitochondrial ferritin in neurodegenerative diseases
Pankiewicz et al. Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice
Tang et al. A mechanistic survey of Alzheimer's disease
Liu et al. Is huntingtin dispensable in the adult brain?
Clabough Huntington’s disease: the past, present, and future search for disease modifiers
Emamzadeh et al. Effects of different isoforms of apoE on aggregation of the α‐synuclein protein implicated in Parkinson’s disease
Mckenzie-Nickson et al. Bis (thiosemicarbazone) metal complexes as therapeutics for neurodegenerative diseases
Mata Functional interplay between plasma membrane Ca2+-ATPase, amyloid β-peptide and tau
Ellis et al. Mechanistic insights into toxicity pathways induced by nanomaterials in Daphnia magna from analysis of the composition of the acquired protein corona
Ajish et al. A novel hybrid peptide composed of LfcinB6 and KR-12-a4 with enhanced antimicrobial, anti-inflammatory and anti-biofilm activities
Fogerson et al. Reducing synuclein accumulation improves neuronal survival after spinal cord injury
Kakinen et al. Physical and toxicological profiles of human IAPP amyloids and plaques
Zhang et al. Secondary chemical bonding between insoluble calcium oxalate and carbonyl oxygen atoms of GLY and VAL residues triggers the formation of Aβ aggregates and their deposition in the brain